Survey on drug utilization in outpatient treatment of type 2 diabetes: A cross-sectional study at a medical center, Vietnam, 2024 - 2025
Các tác giả
DOI: https://doi.org/10.59294/HIUJS20250110Từ khóa:
type 2 diabetes mellitus, drug-drug interactions, outpatient, prescription patternsTóm tắt
Background: The increasing prevalence of type 2 diabetes rates emphasizes the need to assess outpatient drug utilization patterns and potential drug-drug interaction (DDIs). Objective: This study aimed to determine the antidiabetic drug utilization patterns, assess the prevalence of potential drug-drug interactions, and analyze factors associated with DDIs in outpatient prescriptions for type 2 diabetes mellitus (T2DM). Materials and methods: A cross-sectional descriptive study was conducted using retrospective data from outpatients with T2DM treated at the District 5 Medical Center, Ho Chi Minh City, between August 2024 and February 2025. Prescriptions were analyzed for drug utilization patterns and screened for potential DDIs using Drugs.com and Medscape databases. Patient demographics and comorbidities were assessed as determinants of DDIs. Results: A total of 415 outpatient prescriptions were reviewed. The male-to-female ratio was 1:1.20, with more than half of the patients aged ≥ 65 years (52.8%). Dual therapy predominated (67.7%), and biguanides were prescribed in 90.8% of cases. Potential DDIs were identified in 68.9% of prescriptions via Drugs.com and 74.7% via Medscape, the majority classified as moderate. Hypertension, cardiovascular disease, renal impairment, and biguanide use were significantly associated with an increased risk of DDIs. Conclusion: Antidiabetic prescribing at the district level is characterized by widespread use of dual therapy and a high prevalence of potential DDIs. Strengthening clinical pharmacy services and implementing systematic prescription reviews are essential to optimize T2DM management and minimize the risks associated with drug interactions.
Abstract
Background: The increasing prevalence of type 2 diabetes rates emphasizes the need to assess outpatient drug utilization patterns and potential drug-drug interaction (DDIs). Objective: This study aimed to determine the antidiabetic drug utilization patterns, assess the prevalence of potential drug-drug interactions, and analyze factors associated with DDIs in outpatient prescriptions for type 2 diabetes mellitus (T2DM). Materials and methods: A cross-sectional descriptive study was conducted using retrospective data from outpatients with T2DM treated at the District 5 Medical Center, Ho Chi Minh City, between August 2024 and February 2025. Prescriptions were analyzed for drug utilization patterns and screened for potential DDIs using Drugs.com and Medscape databases. Patient demographics and comorbidities were assessed as determinants of DDIs. Results: A total of 415 outpatient prescriptions were reviewed. The male-to-female ratio was 1:1.20, with more than half of the patients aged ≥ 65 years (52.8%). Dual therapy predominated (67.7%), and biguanides were prescribed in 90.8% of cases. Potential DDIs were identified in 68.9% of prescriptions via Drugs.com and 74.7% via Medscape, the majority classified as moderate. Hypertension, cardiovascular disease, renal impairment, and biguanide use were significantly associated with an increased risk of DDIs. Conclusion: Antidiabetic prescribing at the district level is characterized by widespread use of dual therapy and a high prevalence of potential DDIs. Strengthening clinical pharmacy services and implementing systematic prescription reviews are essential to optimize T2DM management and minimize the risks associated with drug interactions.
Tài liệu tham khảo
[1] American Diabetes Association, "Diagnosis and classification of diabetes mellitus," Diabetes care,
vol. 33, no. Supplement_1, pp. S62-S69, 2010. doi: https://doi.org/10.2337/dc10-S062.
[2] P. Saeedi, I. Petersohn, P. Salpea, B. Malanda, S. Karuranga, N. Unwin, S. Colagiuri, L. Guariguata,
A. A. Motala, and K. Ogurtsova, "Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: Results from the International Diabetes Federation Diabetes Atlas," Diabetes Research Clinical Practice, vol. 157, p. 107843, 2019. doi: https://doi.org/10.1016/j.diabres.2019.107843.
[3] N. B. Ngoc, Z. L. Lin, and W. Ahmed, "Diabetes: what challenges lie ahead for Vietnam?," Annals of Global Health, vol. 86, no. 1, p. 1, 2020. doi: https://doi.org/10.5334/aogh.2526.
[4] H. Van Minh, D. Lan Huong, K. Bao Giang, and P. Byass, "Economic aspects of chronic diseases in Vietnam," Global Health Action, vol. 2, no. 1, p. 1965, 2009. doi: https://doi.org/10.3402/gha.v2i0.1965.
[5] Trung tâm Kiểm soát bệnh tật thành phố Hồ Chí Minh. (2023, 25/08/2025). TP.HCM: Tỷ lệ bệnh nhân đái tháo đường đạt mục tiêu điều trị gia tăng. Available: https://hcdc.vn/tphcm-ty-le-benh-nhan-dai-thao-duong-dat-muc-tieu-dieu-tri-gia-tang-ZqNrA0.html. [Truy cập ngày 25/08/2025].
[6] N. T. Uyên, Ð. V. Mãi, L. T. Hoa, and T. T. M. Lệ, "Khảo sát tình hình sử dụng thuốc điều trị đái tháo đường típ 2 và tương tác thuốc tại Khoa Khám bệnh - Bệnh viện Đa khoa Thị xã Buôn Hồ năm 2023," Tạp chí Y học Việt Nam, tập 543, số 2, 2024. doi: https://doi.org/10.51298/vmj.v543i2.11427.
[7] N. V. Em and N. T. T. Hýõng, "Tình hình sử dụng thuốc trên bệnh nhân đái tháo đường tuýp 2 điều trị ngoại trú tại Trung tâm Y tế huyện Cù Lao Dung, tỉnh Sóc Trăng," Tạp chí Nghiên cứu khoa học và Phát triển kinh tế Trường Đại học Tây Đô, số 19, tr. 150-163, 2024.
[8] N. T. T. Thuỷ, L. H. Duy, and P. H. Thắm, "Đánh giá tình hình sử dụng thuốc điều trị tăng huyết áp tại phòng khám tim mạch Bệnh viện Nhân dân Gia Định nửa đầu năm 2023," Tạp Chí Khoa học Trường Đại học Quốc tế Hồng Bàng, tr. 79-88, 2024.doi: https://doi.org/10.59294/HIUJS.29.2024.610.
[9] Rana J, Oldroyd J, Islam Md Momin, Tarazona-Meza Carla E, and Islam Rakibul M, "Prevalence of hypertension and controlled hypertension among United States adults: evidence from NHANES 2017-18 survey," International Journal of Cardiology Hypertension, vol. 7, p. 100061, 2020.doi: https://doi.org/10.1016/j.ijchy.2020.100061
[10] N. Kothari and B. Ganguly, "Potential drug-drug interactions among medications prescribed to hypertensive patients," Journal of clinical and diagnostic research: JCDR, vol. 8, no. 11, p. HC01, 2014.doi: https://doi.org/10.7860/JCDR/2014/10032.5091.
[11] L. Al-Musawe, C. Torre, J. P. Guerreiro, … , and A. P. Martins, "Drug-drug interactions and inappropriate medicines impact on glycemic control and kidney function in older adults with diabetes-attending specialty care institution," European Journal of Clinical Pharmacology, vol. 77, no. 9, pp. 1397-1407, 2021.doi: https://doi.org/10.1007/s00228-021-03107-y.
[12] M. Sheikh-Taha and M. Asmar, "Polypharmacy and severe potential drug-drug interactions among older adults with cardiovascular disease in the United States," (in eng), BMC Geriatr, vol. 21, no. 1, p. 233, Apr 7 2021.doi: https://doi.org/10.1186/s12877-021-02183-0.
[13] Ð. T. B. Nhi, N. T. T. Tâm, N. C. Huân, …, và L. T. Khoảng, "Khảo sát Tương tác thuốc trong kê đơn điều trị đái tháo đường ở bệnh nhân ngoại trú tại Bệnh viện Đại học Y Dược Buôn Ma Thuộc năm 2023 - 2024," TNU Journal of Science and Technology, tập 230, số 05, tr. 463-470, 2025.
[14] B. Papotti, C. Marchi, M. P. Adorni, and F. Potì, "Drug-drug interactions in polypharmacy patients: The impact of renal impairment," Current research in pharmacology and drug discovery, vol.2,p. 100020, 2021. doi: https://doi.org/10.1016/j.crphar.2021.100020
Tải xuống
Tải xuống: 0
Đã xuất bản
Cách trích dẫn
Số
Chuyên mục
